Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 17/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 10/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20285631 | 1.00 | ADRB2 (0.61) | ADRB2ADRB1KDM4EMEN1LMNA | |
| SCHEMBL1310646 | 1.00 | ADRB2 (0.61) | ADRB2ADRB1KDM4EMEN1LMNA | |
| Fluoride SCHEMBL28425860 | 0.98 | ADRB2 (0.60) | ADRB2ADRB1KDM4EMEN1LMNA | |
| Hydrochloric Acid SCHEMBL14166246 | 0.98 | ADRB2 (0.60) | ADRB2ADRB1KDM4EMEN1LMNA | |
| Hydrochloric Acid SCHEMBL5681928 | 0.98 | ADRB2 (0.60) | ADRB2ADRB1KDM4EMEN1LMNA | |
| Acetic Acid SCHEMBL98724 | 0.93 | ADRB2 (0.56) | ADRB2ADRB1KDM4EMEN1LMNA | |
| Acetic Acid SCHEMBL99495 | 0.93 | ADRB2 (0.56) | ADRB2ADRB1KDM4EMEN1LMNA | |
| SCHEMBL14290919 | 0.88 | ADRB2 (0.70) | ADRB2ADRB1KDM4EMEN1LMNA | |
| SCHEMBL6455562 | 0.86 | ADRB2 (0.60) | ADRB2ADRB1KDM4EMEN1LMNA | |
| SCHEMBL20730387 | 0.85 | ADRB2 (0.66) | ADRB2ADRB1SLC6A2ADRA1DHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | claimed |
| US-20230322745-A1 | FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| EP-4219485-A1 | FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-02 | — | — | EP | disclosed |
| US-11447485-B2 | Class of bifunctional compounds with quanternary ammonium salt structure | BEIJING SHOWBY PHARMACEUTICAL CO., LTD. (CN) | 2022-09-20 | — | — | US | disclosed |
| EP-3735406-B1 | A PROCESS FOR PREPARATION OF 5-(2-(SUBSTITUTED-AMINO)-1-HYDROXYETHYL)-8-(SUBSTITUTED-OXY) QUINOLIN-2(1H)-ONE | DEVA HOLDING AS (TR) | 2022-05-11 | — | — | EP | disclosed |
| EP-3256464-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2022-05-11 | — | — | EP | disclosed |
| EP-3256464-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2022-05-11 | — | — | EP | disclosed |
| CN-110087729-B | Bifunctional compound with quaternary ammonium salt structure | 北京硕佰医药科技有限责任公司 | 2022-04-05 | — | — | CN | disclosed |
| EP-3383867-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2021-04-14 | — | — | EP | disclosed |
| EP-3484879-B1 | HYDROXYQUINOLINONE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2020-12-30 | — | — | EP | disclosed |
| US-20110275623-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275623-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275623-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275622-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| EP-1613599-B1 | A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES | NOVARTIS AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| EP-1791820-B1 | ENANTIOSELECTIVE PREPARATION OF QUINOLINE DERIVATIVES | NOVARTIS AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| EP-1599450-B1 | PROCESS FOR PREPARING 5-[(R)-2-(5,6-DIETHYL-INDAN-2-YLAMINO)-1-HYDROXY-ETHYL]-8-HYDROXY-(1H)-QUINOLIN-2-ONE SALTS, USEFUL AS ADRENOCEPTOR AGONISTS | NOVARTIS AG (CH) | 2009-06-24 | — | — | EP | disclosed |
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| EP-1641465-A2 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | Theravance, Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005025555-A2 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | THERAVANCE, INC. (US) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275622-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | BDKRB2, BDKRB1, MRGPRX2 | ADRB2 16/4885ADRB1 15/4885KDM4E 3143/4885 |
| US-11447485-B2 | Class of bifunctional compounds with quanternary ammonium salt structure | AGTR2, AGTR1, ADRB2 | ADRB2 3/4885ADRB1 4/4885KDM4E 3505/4885 |
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885ADRB1 2/4885KDM4E 3961/4885 |
| US-20110275623-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | BDKRB2, BDKRB1, P2RX7 | ADRB2 40/4885ADRB1 44/4885KDM4E 2797/4885 |
| US-20230322745-A1 | FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | CYP3A43, ABCB1, ABCB11 | ADRB2 540/4885ADRB1 1001/4885KDM4E 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.